Does metformin have a "buffer effect" on serum TSH levels in euthyroid diabetic patients?

Area of Science:

• Endocrinology
• Metabolic Disorders
• Pharmacology

Background:

• Previous studies indicated metformin's TSH-lowering effect in type 2 diabetes (DM2) patients, primarily those with hypothyroidism on levothyroxine (LT4) treatment and elevated TSH.
• This effect was noted to be absent upon drug discontinuation and only present with elevated TSH levels.

Purpose of the Study:

• To investigate the impact of metformin on serum TSH levels in euthyroid DM2 patients.
• To determine if metformin influences TSH in individuals without pre-existing thyroid dysfunction.

Main Methods:

• A retrospective analysis of 278 DM2 patients (110 females) across seven Spanish primary health centers.
• Serum TSH levels were measured before and one year after initiating metformin treatment.
• Patients were stratified into four clusters based on initial TSH levels; none received LT4.

Main Results:

• A statistically significant increase in TSH levels was observed post-metformin treatment (2.00 ± 0.76 mU/L to 2.20 ± 0.87 mU/L; P <0.001).
• This TSH elevation trend was prominent in clusters with lower baseline TSH (clusters 1 and 2) but not in clusters 3 and 4.
• A mathematical model suggested a TSH threshold of 3.00 mU/L for this effect.

Conclusions:

• Metformin may exert a
• buffer effect
• on TSH secretion in euthyroid individuals with DM2.
• This study highlights a previously unreported TSH behavior associated with metformin use in this patient population.